Camrelizumab combined with apatinib and albumin-bound paclitaxel followed by camrelizumab plus apatinib as first-line therapy for unresectable or metastatic pancreatic cancer.

被引：0

作者：

Shen, Bo ^{[1
]}

Wu, Yuan ^{[1
]}

机构：

[1] Nanjing Med Univ, Affiliated Canc Hosp, Jiangsu Canc Hosp, Internal Med Oncol, Nanjing, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

703

引用

页码：703 / 703

页数：1

共 50 条

[41] A clinical retrospective study of anlotinib in combination with gemcitabine and albumin-bound paclitaxel for the first-line treatment of advanced pancreatic cancer
Zheng, Yawen
Zhou, Yuhan
Xia, Haiyan
Liang, Wei
Wei, Xiaowei
Zhou, Jin
GASTROINTESTINAL TUMORS, 2025, 12
[42] First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study
Xiaofeng Chen
Hao Xu
Xiaobing Chen
Tongpeng Xu
Yitong Tian
Deqiang Wang
Fen Guo
Kangxin Wang
Guangfu Jin
Xiao Li
Rong Wang
Fengyuan Li
Yongbin Ding
Jie Tang
Yueyu Fang
Jing Zhao
Liang Liu
Ling Ma
Lijuan Meng
Zhiguo Hou
Rongrong Zheng
Yang Liu
Ni Guan
Bei Zhang
Shuang Tong
Shiqing Chen
Xing Li
Yongqian Shu
Signal Transduction and Targeted Therapy, 9
[43] Apatinib in combination with docetaxel and S1 chemotherapy in the first-line treatment of metastatic gastric cancer.
Xia, Ling
Gao, Yu
Gong, Jun
Dai, Jing
Peng, Jin
He, Lilin
Chen, Weidong
Gong, Wei
Yang, Lei
Wang Wen-Bo
Jiang, Huangang
Xu, Hui
Wang, Qing-Yun
Wu, Han
Wang, You
Wu, Lu
Zhou, Fuxiang
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[44] Phase II trial of nab-paclitaxel (nanoparticle albumin-bound paclitaxel (ABX)) plus capecitabine (XEL) in first-line treatment of metastatic breast cancer (MBC)
Somer, B. G.
Schwartzberg, L. S.
Arena, F.
Epperson, A.
Fu, D.
Fortner, B. V.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[45] Phase II clinical trial of S-1 plus nanoparticle albumin-bound paclitaxel as first-line chemotherapy for patients with metastatic gastric cancer
Xu, Rui-hua
He, Ming-ming
Zhang, Dong-sheng
Wang, Feng
Jin, Ying
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[46] Efficacy and safety of camrelizumab combined with albumin-bound paclitaxel as third- or later-line regimen in patients with advanced non-small cell lung cancer
Zhu, Jianfeng
Yu, Yanyan
Mei, Jiaqi
Chen, Shiyao
Li, Jiufei
Jiang, Sicong
FRONTIERS IN IMMUNOLOGY, 2023, 14
[47] Study protocol: A single-arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first-line immunotherapy
Xing, Puyuan
Wang, Mengzhao
Zhao, Jun
Zhong, Wei
Chi, Yujia
Xu, Ziyi
Li, Junling
THORACIC CANCER, 2021, 12 (20) : 2825 - 2828
[48] A clinical study of camrelizumab combined with chemotherapy and sequential apatinib in the second-line treatment of patients with advanced non-small cell lung cancer.
Pan, Yueyin
Jiang, Fengshou
Du, Yingying
Wang, Yong
Liu, Hu
Wang, Zishu
Liang, Hui
Bi, Minghong
Yao, Yiwei
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[49] Camrelizumab plus apatinib for advanced renal cell carcinoma patients after first-line tyrosine kinase inhibitor treatment failure: A multicenter phase II trial
Jiang, Lijuan
Zheng, Xia
Wei, Wensu
Peng, Yulu
Wang, Deling
Zhang, Zhiling
Guo, Shengjie
Han, Hui
Cai, Xiuyu
Zhou, Fangjian
Dong, Pei
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[50] Economic evaluation of camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma in the United States and China
Wei, Jingxuan
Xu, Kai
Lin, Yingtao
Liu, Qiang
Zhou, Chongchong
Zhang, Pei
Ma, Rui
Zhang, Mengdie
Zhang, Lingli
Li, Xin
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2024, 46 (05) : 1189 - 1199

← 1 2 3 4 5 →